Tech Company Financing Transactions
Ayala Pharmaceuticals Funding Round
On 5/29/2019, Ayala Pharmaceuticals received $30 million in Series B funding from Novartis Venture Fund, aMoon Partners and Harel Insurance.
Transaction Overview
Company Name
Announced On
5/29/2019
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
The new capital will fuel Ayala's plans to advance the clinical development of lead product candidate AL101, a pan-Notch inhibitor that is currently being evaluated for adenoid cystic carcinoma (ACC).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1313 N. Market St. 5100
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Website
Email Address
Overview
Ayala (Nasdaq: AYLA) is a clinical stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers. We look to target rare and unique cancers, in which the Notch activation pathway has been dysregulated. Notch is a proven oncogenic driver in defined cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roni Mamluk
Chief Financial Officer
Yossi Maimon
Chief Medical Officer
Andrea Vergara-Silva
Vice President
David Caron
VP - Bus. Development
Dana Gelbaum
VP - Human Resources
Irit Klipper-Avni
VP - R & D
Joel Kaye
Browse more venture capital transactions:
Prev: 5/29/2019: New Energy Equity venture capital transaction
Next: 5/29/2019: Medically Home venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs